RecruitingPhase 2NCT07207408
Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age
Studying Plague
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Dynavax Technologies Corporation
- Intervention
- rF1V-1018(biological)
- Enrollment
- 148 target
- Eligibility
- 18-55 years · All sexes
- Timeline
- 2025 – 2026
Study locations (3)
- AMR- Miami, Miami, Florida, United States
- AMR- El Dorado, El Dorado, Kansas, United States
- AMR- Las Vegas, Las Vegas, Nevada, United States
Collaborators
United States Department of Defense
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07207408 on ClinicalTrials.govOther trials for Plague
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06943378Ph1, Randomized, Double-Blind and Controlled, Dose Escalation and Expansion Study to Assess the Safety and Pharmacokinetics of JST-010 in Healthy AdultsJust-Evotec Biologics
- RECRUITINGNANCT06083649The Dental Care Revolution: Health Education Using AI or Humanized Counseling on Plague Control and Periodontal Treatment Outcome in Patients With Periodontal DiseaseKaohsiung Medical University Chung-Ho Memorial Hospital